Introduction
The interferon regulatory factor (IRF) family is composed of several structurally related proteins including IRF-1 (Harada et al., 1989; Pine et al., 1990) , IRF-2 (Harada et al., 1989) , ICSBP (Nelson et al., 1993) , ISGF3g (Veals et al., 1992) , IRF-3 (Grant et al., 1995) , IRF-7 (Zhang and Pagano, 1997) , Pip (Eisenbeis et al., 1995) , and LSIRF (Yamagata et al., 1996) , which play a vital role in the regulation of interferon (IFN)-and virus-mediated responses. IRF-1 and IRF-2 are generally regarded as a pair of mutually antagonizing transcription factors. IRF-1 functions as a transcriptional activator of Type I IFNs and other IFN stimulated genes (ISGs), whereas IRF-2 antagonizes IRF-1 activation by competing with IRF-1 for its DNA binding site (Harada et al., 1989 (Harada et al., , 1990 Tanaka et al., 1993; Taniguchi et al., 1995 Taniguchi et al., , 1997 . IRF-1 and IRF-2 are also implicated in cell growth control with IRF-1 displaying tumor suppressor activity (Willman et al., 1993; Kirchho et al., 1993; Harada et al., 1993 Harada et al., , 1994 Tanaka et al., 1996; Taniguchi et al., 1995 Taniguchi et al., , 1997 and IRF-2 having oncogenic potential Taniguchi et al., 1995 Taniguchi et al., , 1997 . IRF-1 and IRF-2 have highly homologous N-terminal DNA binding motifs (Harada et al., 1989) . The Cterminal portions are related but are less homologous. The C-terminal region in IRF-1 is responsible for transcriptional activation whereas the C-terminal region in IRF-2 is a transcriptional repression domain rich in basic residues (Harada et al., 1989) . However, functional studies of C-terminal truncated IRF-2 have revealed a latent activation domain in the central region of IRF-2, indicating that under certain circumstances, IRF-2 may function as a transcriptional activator (Yamamoto et al., 1994) . In addition, other recent evidence demonstrates that IRF-2 is not always a transcriptional repressor. IRF-2 activates promoters for Epstein-Barr virus nuclear antigen-1 (EBNA1) (Schaefer et al., 1997) , histone H4 (Vaughan et al., 1995 (Vaughan et al., , 1998 , and murine muscle vascular cell adhesion molecule-1 (VCAM-1) (Jesse et al., 1998) .
Both IRF-1 and IRF-2, as well as other IRF family members, exert their transcriptional regulatory activity through binding to the highly conserved interferonresponse element (IRF-E) found in the promoters of various IFN-inducible genes, including the genes for IFN-a/b (Fujita et al., 1988; Taniguchi et al., 1997) , 2'-5'-OAS (Benech et al., 1987) , GBP (Lew et al., 1991; Briken et al., 1995) , iNOS (Xie et al., 1993; Spink and Evans, 1997) , MHC class I (Blanar et al., 1989; Chang et al., 1992) , TAP1 Min et al., 1996; White et al., 1996) , IL-4 (Li-Weber et al., 1994) , IL-6 (Faggioli et al., 1997) , and IL-7 (Aragane et al., 1997) . The IRF-E is also found in the promoters of three constitutively expressed genes: EBNA1 (Schaefer et al., 1997) , histone H4 (Vaughan et al., 1995 (Vaughan et al., , 1998 , and murine muscle VCAM-1 (Jesse et al., 1998) , which are activated by IRF-2. The consensus IRF-E sequence has been established as G(A)AAA G / C T / C GAAA G / C T / C . It is interesting to note that all of the above three genes that are activated by IRF-2 have a G residue at position 11 in their IRF-Es ( Figure  1 ). However, the eects of IRF-2 on other promoters having a G residue at position 11 in their IRF-Es have not yet been determined. Also, there is a C residue at position 11 in the proximal IRF-E of the gp91 phox promoter, a promoter which is activated by IRF-2 (Luo and Skalnik, 1996) .
Class II transactivator (CIITA) activates the expression of the major histocompatibility class II (MHC class II) genes (Steimle et al., 1993 (Steimle et al., , 1994 , which encode cell surface molecules that present antigenic peptides to CD4 + T cells. CIITA also plays an important role in the regulation of other genes that are involved in antigen presentation, such as invariant chain (Ii) (Chin et al., 1995; Lu et al., 1997) and HLA-DM (Chang and Flavell, 1995; Kern et al., 1995; Ting et al., 1997; Westerheide et al., 1997) . Thus, control of CIITA expression dictates the control of the general antigen presentation capability and possibly the immunogenicity of tumor cells. Also, CIITA expression may lead to self-antigen presentation by cells aected in auto-immune diseases. Transcription of the CIITA gene is directed by four tissue-speci®c promoters (Muhlethaler-Mottet et al., 1997) . The CIITA Type IV promoter controls the IFN-g induced expression of CIITA in non-professional antigen presenting cells, such as endothelial cells and fibroblasts (Muhlethaler-Mottet et al., 1997) . Sequence analysis of human and mouse CIITA Type IV promoters identi®ed multiple highly conserved regulatory elements, including a NFkB site, a NF-GMa site, a GAS element, an E-Box, and an IRF-E (Muhlethaler-Mottet et al., 1997). Mutagenesis and reporter gene assays demonstrated the cooperative activation of the CIITA Type IV promoter by STAT1 and USF-1, which bind to the GAS element and E-box of the promoter, respectively (Muhlethaler-Mottet et al., 1998) . The presence of an IRF-E site in the CIITA Type IV promoter suggests the involvement of IRF family members in the regulation of the promoter. The promoter with a mutated IRF-E is not responsive to IFN-g (Muhlethaler-Mottet et al., 1998) . In addition, induction of CIITA by IFN-g was drastically inhibited in multiple tissues from IRF-1 knock-out mice (Hobart et al., 1997; Muhlethaler-Mottet et al., 1998) .
The presence of a G residue at position 11 in the IRF-E of the CIITA Type IV promoter (Figure 1 ) prompted us to investigate the possible role of IRF-2 in the regulation of this promoter. In this study, we performed electrophoretic mobility shift assays (EMSA) and reporter gene assays, demonstrating that IRF-2 activates the CIITA Type IV promoter by binding to the IRF-E. In addition, we found that IRF-1 and IRF-2 can co-occupy the CIITA Type IV promoter IRF-E and synergistically activate this promoter. IRF-1 and -2 co-occupancy of an IRF-E has never been previously reported for any promoter. Similar experiments were performed with the GBP IRF-E, with results similar to those obtained in studying the CIITA Type IV IRF-E. This work has also led to the identi®cation of a mutation in IRF-2 in a human tumor line. IRF-2 has not been previously reported to be mutated in tumor cells.
Results

IRF-1 and IRF-2 bind to the IRF-E of the CIITA Type IV promoter
Mutagenesis analysis has shown that a putative IRF-E is required for CIITA Type IV promoter activation by IFN-g (Muhlethaler-Mottet et al., 1998) . To be certain that CIITA IRF-E binds IRF-1, and to further Figure 1 Diagram of wild-type (CIITA P4/7309, CIITA P4/785) and mutant (mutCIITA P4/785) human CIITA type IV promoter constructs. Positions of conserved regulatory elements and the sequence of the wild-type IRF-E are indicated. Substituted nucleotides of the mutant IRF-E are shown below the wild-type sequence. The bold-type G in the IRF-E represents the conserved G residue at position 11 in the IRF-Es of the promoters of the genes activated by IRF-2
Cooperative IRF-1 and IRF-2 activation of CIITA H Xi et al characterize the IRF-1 and IRF-2 binding to the CIITA IRF-E, we performed an EMSA using in vitro translated IRF-1 and IRF-2 and the 785/+1 region of the CIITA Type IV promoter as probe ( Figure 1 ). An unlabeled mutant IRF-E, used for the competition experiments, was generated by substituting two nucleotides in the wild-type IRF-E (Figure 1 ). Equal amounts of IRF-1 and IRF-2 were added to the binding reactions, as determined by quantifying 35 Smethionine labeled IRF-1 and IRF-2 produced by in vitro translation (data not shown). Both IRF-1 and IRF-2 retarded the labeled probe (Figure 2a) .
One major retarded complex was produced using small amounts of IRF-1 or IRF-2. The complexes could not be abolished by excess unlabeled mutant IRF-E and could be supershifted by anti-IRF-1 or anti-IRF-2 antibody, indicating that they resulted from speci®c binding of IRF-1 or IRF-2 to the IRF-E, respectively. Binding of the CIITA IRF-E by IRF-1 is consistent with conclusions from a recent, related experiment using nuclear extracts rather than in vitro translated IRF-1 (Piskurich et al., 1999) . With the addition of increasing amounts of in vitro translated protein, a second, more slowly migrating complex became apparent. In the case of IRF-2, the formation of the slower mobility complex was not prevented by excess unlabeled mutant lane 14) , and this slower complex was supershifted by anti-IRF-2 antibody (Figure 2a, lane 16) , indicating that this complex, like the faster migrating complex, resulted from speci®c binding of IRF-2 to the CIITA IRF-E. These data strongly indicate that the faster migrating complex is the IRF-E bound by one IRF-2 molecule and that the slower migrating complex represents the co-occupancy of the IRF-E by two IRF-2 molecules, consistent with the recent crystallographic analysis of an IRF-E bound by IRF-2 (Kusumoto and Fujii, 1998) . A previous study has shown that two IRF-1 molecules can simultaneously bind the mouse iNOS IRF-E (Spink and Evans, 1997) . In our experiments with IRF-1, the slower mobility complex could not be detected using 2 ml of in vitro translated IRF-1 ( Figure  2a , lane 4). When 4 ml of IRF-1 were added, a slower mobility complex was detectable. However, the speci®city of this slower mobility complex seen using 4 ml of IRF-1 has not been determined, and thus it could represent either nonspeci®c binding or the cooccupancy of the IRF-E by two molecules of IRF-1.
IRF-2 activates the CIITA Type IV promoter
To determine whether the CIITA Type IV promoter could be activated by IRF-1 or IRF-2, we cotransfected IRF-1 (Cha and Deisseroth, 1994) and IRF-2 (Cha and Deisseroth, 1994) expression vectors with the CIITA P4/785 promoter luciferase construct (Figure 1 ), using the following amounts of DNA: 5 mg IRF-1 (IRF-1), 5 mg IRF-2 (IRF-2), or 5 mg IRF-1 and 5 mg IRF-2 (IRF-1+IRF-2). In all cases, 5 mg of the CIITA P4/785 promoter luciferase construct were co-transfected with the expression vector(s). As a negative control, 5 mg of the empty vector were co-transfected with the CIITA P4/785 promoter luciferase construct. DNAs were transfected into 2610 6 MIAPaCa-2 cells by calcium phosphate precipitation. Luciferase activity was assayed 24 h after co-transfection. Additional details are in Materials and methods. Fold activation of the promoter was measured by dividing the luciferase activity of expression vector transfected cells by that of empty vector transfected cells. Results shown are the means of ®ve independent experiments with standard errors of the means. (c) IRF-2 does not activate the mutCIITA P4/785 promoter luciferase construct containing the mutant IRF-E. MIAPaCa-2 cells (2610 6 ) were co-transfected with 5 mg of IRF-2 expression vector and 5 mg of mutCIITA P4/785 promoter luciferase construct (Figure 1 ) (Mut) and luciferase activity was assayed 24 h after co-transfection. As a positive control, 5 mg of IRF-2 expression vector were co-transfected with 5 mg of CIITA P4/785 promoter luciferase construct (WT). Fold activation of the promoter was measured as described in (b) . The data represent the means of ®ve independent experiments with standard errors of the means Cooperative IRF-1 and IRF-2 activation of CIITA H Xi et al which spans nucleotide 785 to +1 of the promoter (Figure 1) . The pancreatic carcinoma cell line, MIAPaCa-2 was employed as the recipient cell in this co-transfection experiment, as well as in all other transfection experiments in this study, because this cell line is highly transfectable. Data indicated that both IRF-1 and IRF-2 activated the CIITA P4/785 promoter to a similar extent (Figure 2b ). Simultaneous co-transfection of both IRF-1 and IRF-2 led to a slight increase over the expected, additive activation of the CIITA P4/785 promoter by co-transfection of IRF-1 or IRF-2 alone. The mutCIITA P4/785 promoter luciferase construct with the mutated IRF-E (Figure 1) was not activated by co-transfection of the IRF-2 expression vector (Figure 2c ), indicating that IRF-2 activation of the wild-type promoter is mediated through binding of IRF-2 to the IRF-E.
Cooperative activation of the CIITA Type IV promoter by IRF-1 and IRF-2
We considered the possibility that the CIITA P4/785 promoter did not include enough of the upstream region to detect cooperative activation by IRF-1 and IRF-2. Thus, we co-transfected the IRF-1 and IRF-2 expression vectors into MIAPaCa-2 cells with a longer CIITA Type IV promoter reporter construct, CIITA P4/7309, which corresponds to positions 7309 to +38 of the promoter. In addition to the IRF-E, this construct also encompasses other DNA elements, e.g., a NFkB site, a NF-GMa site, a GAS element and an E box, not present in the CIITA P4/785 promoter reporter construct (Figure 1 ). The co-transfection experiments revealed several interesting things. First, co-transfection of the IRF-1 expression vector alone did not activate the CIITA P4/7309 promoter luciferase construct (Figure 3a) , although IRF-1 was able to activate the CIITA P4/785 promoter ( Figure  2b ), indicating that a negative regulatory element in the 7309 to 785 region of the promoter interferes with IRF-1 activation. Second, co-transfection of the IRF-1 expression vector in the presence of IFN-g also did not activate the CIITA P4/7309 promoter in MIAPaCa-2 cells (Figure 3b ). This is consistent with the fact that the MIAPaCa-2 cells do not express CIITA in response to IFN-g, due to an as yet uncharacterized defect. However, compared to IRF-1, co-transfection of an equal amount of IRF-2 expression vector alone did lead to the activation of the CIITA P4/7309 promoter, in both IFN-g treated and untreated cells (Figure 3a and b ) . Most importantly, IRF-1 and IRF-2 cooperated in the activation of the CIITA P4/7309 promoter, as highest promoter activity was achieved by simultaneous transfection of IRF-1 and IRF-2 expression vectors. The activation of the promoter, both in the presence and absence of IFN-g, by simultaneous transfection of 5 mg each of IRF-1 and IRF-2 expression vectors was also signi®cantly greater than the activation of the promoter by co-transfection with 10 mg of either the IRF-1 or IRF-2 expression vector alone (data not shown).
Simultaneous occupancy of the CIITA IRF-E by IRF-1 and IRF-2
Co-transfection of IRF-1 and IRF-2 expression vectors had a synergistic eect on the activity of the CIITA Type IV promoter. The most likely molecular mechanism that could account for this result is simultaneous occupancy of the IRF-E by one IRF-1 molecule and one IRF-2 molecule. We refer to this cooccupancy as hetero-occupancy to distinguish it from co-occupancy by two molecules of IRF-1 or two molecules of IRF-2, referred to as homo-occupancy. To assay for the hetero-occupancy of the CIITA IRF-E by IRF-1 and IRF-2, we performed an EMSA by adding a mixture of in vitro translated IRF-1 and IRF-2 to the labeled CIITA IRF-E probe (785/+1) ( Figure 1 ). Because IRF-1 and IRF-2 have very similar molecular weights, the electrophoretic mobility of a complex resulting from IRF-1 and IRF-2 heterooccupancy would not be distinguishable from the mobility of a complex representing IRF homooccupancy. Thus, we in vitro translated a C-terminal truncated IRF-2, termed IRF-2/T, corresponding to amino acids 1 ± 224, including the N-terminal DNA binding domain, for use in an EMSA to detect heterooccupancy. Binding of the C-terminal truncated IRF-2 to the CIITA IRF-E generated complexes containing one and two molecules of the IRF-2/T, each with an electrophoretic mobility greater than the corresponding complex produced with the full-length IRF-2 ( Figure  4a , lanes 14 ± 19), as a result of the reduced molecular weight of IRF-2/T. When increasing amounts of a mixture of IRF-2/T and full-length IRF-1 were added to the probe, a new protein/DNA complex was apparent above the IRF-2/T homo-occupancy complex ( Figure 4a , lanes 6 ± 13). The possibility that this slower mobility complex resulted from IRF-1 homo- S-methionine labeled protein by SDS ± PAGE, were mixed as follows: 0.5 ml (lane 6), 1 ml (lane 7), 1.5 ml (lane 8), 2 ml (lane 9), 2.5 ml (lane 10), 3 ml (lane 11), 3.5 ml (lane 12), 4 ml (lane 13). Other complexes were produced with increasing amounts of either IRF-1 or IRF-2 or IRF-2/T as follows: 1 ml (lanes 3, 14, 17), 2 ml (lanes 4, 15, 18), 4 ml (lanes 5, 16, 19 ). An open triangle, a closed triangle, and an open square represent the occupancy of the IRF-E by a single molecule of IRF-2, IRF-2/T, and IRF-1, respectively. The double open triangles and double closed triangle represent the co-occupancy of the IRF-E by two molecules of IRF-2 and IRF-2/T, respectively. Heterooccupancy of the IRF-E by one IRF-2/T molecule and one IRF-1 molecule is indicated as a closed triangle plus an open square. The rabbit reticulocyte lysate (2 ml) was used as a negative control (lane 2). (b) Hetero-occupancy of the CIITA IRF-E by full-length IRF-1 and full-length IRF-2. A mixture of 5 ml and 1 ml of in vitro translated full-length IRF-1 and IRF-2, respectively, was analysed by EMSA (lane 5), using the 785/+1 region of the CIITA type IV promoter as probe (Figure 1 ), as in (a) above. For antibody supershift assays, the protein mixture was ®rst incubated with the probe for 30 min at 308C followed by incubation with either anti-IRF-1 (lane 6) or anti-IRF-2 (lane 7) antibody, or both (lane 8) for another 30 min at room temperature. For comparison, either 5 ml of IRF-1 (lane 3) or 1 ml of IRF-2 (lane 4) were separately mixed with the probe. Triangles and squares, used to designate the complexes, are as in (a). (c) Hetero-occupancy of the CIITA IRF-E by IRF-1 and IRF-2 in nuclear extracts. EMSA was performed with 10 mg of nuclear extract from the CIITA inducible pancreatic carcinoma cell line, BxPC-3, using the 785/+1 region of the CIITA type IV promoter as probe (Figure 1 To determine whether full-length IRF-2 can also occupy the CIITA IRF-E with IRF-1, we performed an EMSA using in vitro translated full-length IRF-1 and IRF-2. To reduce the background of IRF-2 homooccupancy complex that would interfere with the detection of the hetero-occupancy complex, the ratio of IRF-1 to IRF-2 was increased. A mixture of 5 ml and 1 ml of in vitro translated full-length IRF-1 and IRF-2, respectively, formed a complex at the cooccupancy position (Figure 4b , lane 5). This complex was completely supershifted by both anti-IRF-1 and anti-IRF-2 antibody (Figure 4b , lanes 6 and 7), indicating that the complex was composed of both IRF-1 and IRF-2 (hetero-occupancy). Also, the complex produced by binding of a single IRF-2 molecule was substantially reduced (Figure 4b ; compare lanes 4 and 5), indicating that almost all the IRF-2 molecules occupied the IRF-E with IRF-1.
To determine whether the hetero-occupancy could occur using proteins from a nuclear extract, we conducted an EMSA using the nuclear extract prepared from the CIITA inducible pancreatic tumor line, BxPC-3, which has a background level of IRF-1 (and CIITA) expression in the absence of IFN-g. A cooccupancy complex was formed when no antibody was added (Figure 4c, lane 3) . The intensity of the cooccupancy complex was almost completely abolished with anti-IRF-1 antibody (Figure 4c , lane 1) and was completely abolished by the anti-IRF-2 antibody ( Figure 4c , lane 2). These results indicate that the large portion of the complex at the co-occupancy position in the EMSA represented the heterooccupancy complex of IRF-1 and IRF-2, which could be supershifted by either anti-IRF-1 or anti-IRF-2 antibody.
Cooperative activation of human GBP promoter and co-occupancy of the GBP IRF-E by IRF-1 and IRF-2 CIITA is among a group of genes, including EBNA1 (Schaefer et al., 1997) , histone H4 (Vaughan et al., 1995 (Vaughan et al., , 1998 , and murine muscle VCAM-1 (Jesse et al., 1998) , which are activated by IRF-2 and contain a G residue at position 11 of their IRF-Es. The human guanylate binding protein (GBP) promoter IRF-E also has a G residue at position 11 and is thought to be strongly activated by IRF-1. Thus, we examined whether IRF-1 and IRF-2 could also cooperatively activate the GBP promoter. A GBP promoter reporter construct, hGBP-Luc, which spans 7216 to +19 region of the human GBP promoter, was cotransfected with the IRF-1 or IRF-2 expression vector, or both, into MIAPaCa-2 cells. Overexpression of IRF-1 or IRF-2 only led to minor activation of the promoter (Figure 5a ). However, simultaneous overexpression of IRF-1 and IRF-2 led to a synergistic activation of the promoter, indicating that the GBP promoter, like the CIITA Type IV promoter, was cooperatively activated by IRF-1 and IRF-2.
To determine whether IRF-1 and IRF-2 could cooccupy the hGBP IRF-E, we performed an EMSA using a mixture of in vitro translated full length IRF-1 and C-terminal truncated IRF-2 (IRF-2/T), as in the above analysis of IRF-1 and IRF-2 co-occupancy of the CIITA IRF-E (Figure 4a) . A labeled oligonucleotide spanning 7147 to 7102 region of the GBP promoter including the IRF-E was used as probe. For competition experiments, 80-fold molar excess unlabeled oligonucleotides containing either the wild-type GBP IRF-E or the mutant IRF-E (see Materials and methods) were pre-incubated with the proteins before the addition of the probe. The in vitro translated IRF-1, IRF-2, and IRF-2/T were also subjected to the binding reactions separately to facilitate the distinguishing of the IRF-1 and IRF-2/T hetero-occupancy complex from the IRF-1 homo-occupancy complex. Similar to the CIITA IRF-E, IRF-1 binds to hGBP IRF-E less eciently than IRF-2. The co-occupancy of hGBP IRF-E by two molecules of IRF-2 to IRF-2/T could be detected using 4 ml of in vitro translated IRF-2 or IRF-2/T (Figure 5b, lanes 17, 19 and lanes 23, 25,  respectively) . However, the co-occupancy of hGBP IRF-E by two molecules of IRF-1 was not detectable with 4 ml of in vitro translated IRF-1 (Figure 5b, lanes 3,  5) . When increasing amounts of a mixture of IRF-1 and IRF-2/T were added to the probe, a new complex was apparent above the IRF-2/T homo-occupancy complex (Figure 5b, lanes 7 ± 14) . This complex migrated slightly below the IRF-2 homo-occupancy complex and slightly above the complex resulting from non-speci®c binding of the probe by the lysate (indicated as NS, Figure 5b ), indicating that this new complex resulted from the cooccupancy of the IRF-E by one molecule of IRF-1 and one molecule of IRF-2/T.
Defective CIITA and GBP induction in a pancreatic tumor cell line with a mutant IRF-2 During a routine screen of pancreatic tumor cell lines for IFN-g inducibility of CIITA and HLA-DRA and -DRB mRNAs, we found that about half of these cell lines were noninducible for CIITA mRNA as well as DR mRNAs (data not shown), including the pancreatic tumor line, Hs766T. Lack of CIITA inducibility in Hs766T was determined by RPA ( Figure 6a) . We considered the possibility that lack of CIITA inducibility in Hs766T was traceable to an IRF defect. We compared the IRF-1 and IRF-2 DNA binding activities of Hs766T with those of CIITA inducible pancreatic tumor cell lines, AsPC-1 and Capan-1, using nuclear extracts prepared from IFN-g A B Figure 5 (a) Cooperative activation of the human GBP promoter by IRF-1 and IRF-2. Expression vectors for IRF-1 and IRF-2 were co-transfected with the human GBP promoter luciferase construct (7216 to +19), hGBP-Luc, using the following amounts of DNA: 5 mg IRF-1 (IRF-1), 5 mg IRF-2 (IRF-2), or 5 mg IRF-1 and 5 mg IRF-2 (IRF-1+IRF-2). In all cases, 5 mg of hGBP-Luc construct were co-transfected with the expression vector(s). As a negative control, 5 mg of the empty vector were co-transfected with hGBP-Luc construct. DNAs were transfected into 2610 6 MIAPaCa-2 cells by calcium phosphate precipitation as described in Materials and methods. Luciferase activity was assayed 24 h after co-transfection. Fold activation of the promoter was measured by dividing the luciferase activity of expression vector transfected cells by that of empty vector transfected cells. Results shown are the means of ®ve independent experiments with standard errors of the means. (b) Hetero-occupancy of hGBP IRF-E by IRF-1 and IRF-2. In vitro translated full-length IRF-1 and C-terminal truncated IRF-2, IRF-2/T, as described in Figure 4a , were analysed by EMSA using the labeled oligonucleotide spanning 7147 to 7102 region of the human GBP promoter as probe (see Materials and methods). Equal amounts of IRF-1 and IRF-2/T, were mixed as follows: 0.5 ml (lane 7), 1 ml (lane 8), 1.5 m (lane 9), 2 ml (lane 10), 2.5 ml (lane 11), 3 ml (lane 12), 3.5 ml (lane 13), 4 ml (lane 14). To facilitate the distinguishing of IRF-1 and IRF-2/T hetero-occupancy complex from IRF-1 homo-occupancy complex, other binding reactions were performed with increasing amounts of either IRF-1 or IRF-2/T or IRF-2 as follows: 1 ml (lanes 1, 15, 21), 2 ml (lanes 2, 16, 22), 4 ml (lanes 3, 17, 23). To identify the complexes resulting from speci®c binding of the probe by in vitro translated IRF proteins, binding competition and antibody supershifting experiments were performed with 4 ml of in vitro translated IRF-1 (lanes 4 ± 6), IRF-2/T (lanes 18 ± 20), or IRF-2 (lanes 24 ± 26). For competition experiments, 80-fold molar excess unlabeled oligonucleotides containing either the wild-type GBP IRF-E (WT COMP) or the mutated IRF-E (Mut COMP) (see Materials and methods) were pre-incubated with the proteins before the addition of the probe. The anti-IRF-2 antibody did not supershift IRF-2/T bound probe because the antibody is directed against the C-terminal region of IRF-2, which is not present in IRF-2/T. The rabbit reticulocyte lysate (8 ml) was used as a negative control (lane 27). As described in the legend of Figure 4a To identify the basis for the lack of IRF-2 DNA binding activity, we examined the expression of IRF-2 by Western blotting analysis of the same nuclear extracts used for the EMSA. The IRF-2 protein level of Hs766T was comparable to those of CIITA inducible cell lines (Figure 6d) , ruling out the possibility that loss of IRF-2 DNA binding was due to lack of IRF-2 expression in Hs766T. We next considered the possibility that the DNA binding domain of the Hs766T IRF-2 was mutated. We cloned and sequenced the cDNA fragment of Hs766T encoding the DNA binding domain of IRF-2 (see Materials and methods) and found a missense mutation at position 199 (Cha and Deisseroth, 1994) of the IRF-2 cDNA (Figure 7a ), changing the amino acid residue at position 34 (Cha and Deisseroth, 1994) from Phe to Ser. The Phe residue at position 34 occurs in all the members of IRF family (Escalante et al., 1998) . To rule out the possibility that the nucleotide change resulted from mis-incorporation of a nucleotide during RT ± PCR, we analysed the PCR products representing the IRF-2 DNA binding domain of several pancreatic cell lines, including Hs766T. The PCR products were digested with DdeI, as the T to C change in Hs766T generated a novel DdeI site ( Figure  7a) . Digestion of the 356 bp PCR product of the wildtype IRF-2 by DdeI generates 281 and 75 bp fragments, whereas digestion of the PCR product of the mutant IRF-2 generates 168, 113 and 75 bp fragments (Figure 7b ). Only the PCR product generated from Hs766T had the 168, 113, and 75 bp fragments following DdeI digestion (Figure 7b, lane 2) . Sequence analysis of the remainder of the IRF-2 cDNA in Hs766T cell line did not reveal any other mutations (data not shown).
To determine whether this mutation causes the elimination of IRF-2 binding to the CIITA IRF-E, we generated an expression vector with the mutant Hs766T IRF-2 (see Materials and methods) and performed an EMSA with the in vitro translated mutant Hs766T IRF-2 and the wild-type IRF-2. The 785/+1 region of the CIITA Type IV promoter was used as probe. While the wild-type IRF-2 protein bound to the IRF-E, an equal amount of the mutant Hs766T IRF-2, as determined by quantifying 35 Smethionine labeled in vitro translated proteins ( Figure  7c , left panel), could not bind to the IRF-E (Figure 7c , right panel), indicating that this mutation eliminated IRF-2 DNA binding activity. In addition, co-transfection of the mutant Hs766T IRF-2 with CIITA P4/785 into MIAPaCa-2 cells indicated that this mutant IRF-2 could not activate the CIITA promoter (Figure 7d ).
As the experiments described above indicated that IRF-2 also cooperates with IRF-1 in the activation of the human GBP promoter (Figure 5) , we analysed the IFN-g induction of GBP in Hs766T cell line by RPA (Figure 8 ). Compared to the GBP mRNA induction in the CIITA inducible cell lines, GBP mRNA induction by IFN-g in Hs766T was signi®cantly reduced ( Figure  8 and Table 1 ), consistent with cooperative activation of the GBP promoter by IRF-1 and IRF-2, and loss of IRF-2 function in the Hs766T cell line.
Discussion
IRF-2 can act as either a transcriptional activator or repressor by binding to the IRF-Es in the promoters of dierent genes. The purpose of this study was to investigate the role of IRF-2 in the regulation of the CIITA Type IV promoter. We have shown that IRF-2 activates the CIITA Type IV promoter. IRF-2 activates the CIITA P4/785 promoter luciferase construct containing only the IRF-E to the same level as IRF-1 (Figure 2b ). IRF-1 by itself is not able to activate the CIITA P4/7309 promoter luciferase construct, either in the absence or presence of IFN-g (Figure 3 ), although IRF-1 is required for the IFN-g induction of the CIITA gene in mice (Hobart et al., 1997; Muhlethaler-Mottet et al., 1998) . While IRF-2 by itself can activate the 7309/+38 promoter in the absence of IFN-g, the activation is limited (Figure 3a) . IRF-2 synergizes with IRF-1 in the activation of the CIITA P4/7309 promoter (Figure 3 ). This result suggests that IRF-2, like IRF-1, is required for IFN-g induction of CIITA. This idea is consistent with the loss of IRF-2 function in a CIITA noninducible pancreatic tumor cell line, Hs766T (Figures 6 and 7) . However, direct proof of the role of IRF-2 will require rescuing IRF-2/DNA binding activity in human cell lines defective for IRF-2/ DNA binding activity. As the mouse CIITA Type IV promoter has an identical IRF-E (Muhlethaler-Mottet et al., 1997), it would also be of interest to investigate the CIITA inducibility by IFN-g in the IRF-2 knockout mouse.
Our data indicate that, like the CIITA Type IV promoter, the human GBP promoter is cooperatively activated by IRF-1 and IRF-2 (Figure 5a) . This result appears inconsistent with the previous report showing IRF-2 represses IRF-1 activation of an arti®cial IRF-E promoter reporter construct containing three copies of the GBP IRF-E upstream of a TATA box (Wang et al., 1996) . It is possible that cooperative activation of the GBP promoter by IRF-1 and IRF-2 is dependent on other DNA sequences or elements, that may not be present in the arti®cial promoter. The transient transfection experiments indicated that IRF-2, like IRF-1, is required for the activation of the GBP promoter (Figure 5a ). However, loss of IRF-2 Figure 6 Defective IRF-2/IRF-E binding activity in a CIITA noninducible human pancreatic carcinoma cell line, Hs766T. (a) RNase protection assay (RPA) of IFN-g induction of CIITA mRNA in Hs766T. Cytoplasmic RNA (10 mg) prepared from cells either treated with 400 U/ml recombinant human IFN-g (+) or untreated (7) for 48 h was analysed by RPA, as described in Materials and methods. Two CIITA inducible pancreatic cell lines, AsPC-1 and Capan-1, served as positive controls. The g-actin probe served as a control for gel loading. The positions of the protected fragments are indicated. (b) and (c) Loss of IRF-2/CIITA IRF-E binding activity in Hs766T cell. EMSA was performed with 10 mg of crude nuclear extracts prepared from cells untreated or treated with 400 U/ml recombinant human IFN-g for 2 h. The labeled DNA fragment spanning 785 to +1 region of the CIITA type IV promoter was used as probe. Nuclear extracts from IFN-g treated or untreated CIITA inducible pancreatic tumor cell lines, AsPC-1 and Capan-1, served as positive controls. To eliminate the nonspeci®c binding, 80-fold molar excess unlabeled DNA fragments (785/+1) encompassing the mutant CIITA IRF-E (Figure 1 ) was included in all the binding reactions. Distinguishing the IRF-2/DNA complex from the IRF-1/DNA complex was facilitated by antibody supershifting. The complexes (e.g., Figure 6c , lane 1) just below the supershifted IRF-1 or IRF-2 complex (e.g., Figure 6c, lanes 3 and 4) , but above the monomeric IRF-1 or IRF-2 complex, resulted from the binding of the IRF-E by two IRF molecules. These dimeric complexes, as described in Figure 4c , were also supershifted by IRF antibodies. In AsPC-1 cell line, in addition to the complexes described above, another complex was apparent just above the complexes representing the binding of one IRF-1 molecule (Figure 6b, lane 1) . This complex was competed by excess wild-type IRF-E and was only slightly aected by IRF antibodies. The identity of the complex, which is not present in other cell lines, is unknown. (d) Loss of IRF-2 DNA binding in Hs766T is not due to loss of IRF-2 expression. The same nuclear extracts (40 mg) used for the EMSA shown in (b) and (c) were analysed for IRF-2 protein by Western blotting, as described in Materials and methods Cooperative IRF-1 and IRF-2 activation of CIITA H Xi et al function in Hs766T (Figures 6 and 7) reduces but does not abolish IFN-g response of GBP gene ( Figure 8 and Table 1 ). The partial GBP induction by IFN-g could be attributable to activated STAT1, which binds to the GAS element overlapping with the IRF-E (Lew et al., 1991) . A previous report indicated that the GAS element of the GBP promoter could function independently of IRF-E in the IFN-g response of GBP gene (Lew et al., 1991) . Although the GAS element and STAT1 are also required for the IFN-g induction of the CIITA Type IV promoter (Muhlethaler-Mottet et al., 1998; Piskurich et al., 1999) , recent evidence indicates that the CIITA Type IV promoter activation is more dependent on the IRF-E than the GAS element (Piskurich et al., 1999) . STAT1 exerts its functional role in the IFN-g response of the CIITA Type IV promoter possibly through transcriptional activation of IRF-1 (Piskurich et al., 1999) . Thus, the defect that prevents IRF-E occupancy, e.g., by IRF-1 and IRF-2, may have more impact on the CIITA induction than the GBP induction by IFN-g.
DNA binding assays demonstrated that IRF-1 and IRF-2 can simultaneously bind to the IRF-Es of the CIITA Type IV promoter and the human GBP promoter. Another group has reported a failure to detect IRF-2 binding to the IRF-E of the CIITA Type IV promoter (Piskurich et al., 1999) . This discrepancy is possibly due to technical dierences in the experiments or due to the dierential expression of IRF-2 in dierent cell lines or cell types.
The CIITA and GBP IRF-Es are the ®rst two examples of an IRF-E that can be co-occupied by one molecule of IRF-1 and one molecule of IRF-2. Several possible mechanisms, discussed below, could explain the synergistic activation by IRF-1 and IRF-2. These mechanisms are not necessarily mutually exclusive. First, initial binding of one molecule of IRF-2 to the IRF-E may facilitate the binding of one molecule of IRF-1, consistent with the fact that IRF-2 has a substantially higher anity for IRF-Es than does IRF-1. A recent report indicates that the IRF-E of the CIITA Type IV promoter is partially occupied in the unstimulated cell (Piskurich et al., 1999) , possibly by IRF-2, as IRF-2 is constitutively expressed. Sequential binding of two IRF-1 molecules to an IRF-E has been identi®ed in the mouse iNOS IRF-E (Spink and Evans, 1997) , to which binding of the ®rst molecule of IRF-1 is the prerequisite for the binding of the second IRF-1. In this scenario, IRF-2 binding could induce a conformational change speci®c to the CIITA and GBP IRF-Es, which could then facilitate IRF-1 binding. However, this scenario would not exclude the possibility of a physical interaction between IRF-1 and IRF-2 after each is bound to the IRF-E. This hetero-dimerization would be mediated by DNA binding, as IRFs exist as monomers in solution . In several other cases, synergistic activation of a promoter has been explained by the increase in promoter element binding induced by the physical interaction between two transcription factors (Pongubala et al., 1993; Eisenbeis et al., 1995; Neish et al., 1995; Sun et al., 1995; Pongubala and Atchison, 1997) . For example, IRF-1 and NF-kB synergistically activate the endothelial VCAM-1 through physical interaction of IRF-1 with the p50 subunit of NF-kB (Neish et al., 1995) . A second possible mechanism that would explain IRF-1 and IRF-2 synergism is that IRF-2 may relieve the inhibition of IRF-1 activation of the CIITA Type IV promoter. This idea is based on the fact that IRF-1 activates the 7309/+38 region of the promoter only in the presence of IRF-2, although it can activate the 785/+1 region of the promoter independently of IRF-2. Promoter mutagenesis and reporter gene assays have suggested that a NF-GMa site located at 7143 of the CIITA Type IV promoter functions as a negative control element (Muhlethaler-Mottet et al., 1998), although it is not known whether this element speci®cally inhibits IRF-1 activity. Such an IRF-1 inhibitor may not be present in all cell lines, as we and others have identi®ed cell lines where the 7309/+38 region can be activated by IRF-1, unlike in the MIAPaCa-2 line (D Eason, G Blanck, unpublished observations) (Piskurich et al., 1999) . Finally, because both IRF-1 and IRF-2 are able to interact with TFIIB (Wang et al., 1996) , one of the constituents of the basal transcription complex, co-occupancy of an IRF-E by IRF-1 and IRF-2 may enhance the assembly of the basal transcription machinery. This mechanism is distinct from the idea that IRF-2 may only serve to enhance IRF-1 binding in that, in this case, both IRF-1 and IRF-2 would have a direct role in promoter activation, i.e., by maximizing the stability of the transcription pre-initiation complex.
Our study indicates that maximal activation of the human GBP promoter also requires IRF-2 in addition to IRF-1. In this respect, the CIITA Type IV IRF-E and human GBP IRF-E represent a unique class of IRF-Es because they are both responsive to IFN-g, i.e., responsive to IRF-1, and activated by IRF-2. The IRF-E of the EBNA1 promoter, which is activated by IRF-2, is not responsive to IFN-g (Schaefer et al., 1997) . The IRF-Es of the promoters of histone H4 (Vaughan et al., 1995 (Vaughan et al., , 1998 and VCAM-1 (Jesse et al., 1998) , the other two genes that are activated by IRF-2, according to current understanding, are also not responsive to IFN-g (Schaefer et al., 1997) . One interesting question is whether the IRF-Es of these latter three promoters are adjacent to an IRF-1 inhibitory region, present in the CIITA Type IV promoter between nucleotides 7309 and 785, as discussed above. In the case of the EBNA1, histone H4 and VCAM-1 promoters, the IRF-2 containingenhanceosome may not be able to oset the inhibition of IRF-1 function, unlike in the case of the CIITA Type IV promoter.
We have shown that overexpression of IRF-2 can activate the CIITA Type IV promoter luciferase construct in the absence of IRF-1 and IFN-g (Figures  2b and 3a) . These results indicate that overexpression of IRF-2 can bypass the requirement for IRF-1, and thus IFN-g, to activate CIITA. While CIITA expression in the absence of IFN-g leads to expression of MHC class II proteins (Steimle et al., 1994; Chang and Flavell, 1995) and other proteins important for antigen presentation (Chang and Flavell, 1995; Ting et al., 1997) , IFN-g treatment is also required for MHC class II mediated antigen presentation Martinez-Soria et al., 1996) . This raises the question of whether indirect induction of MHC class II by IRF-2 overexpression, independent of the IFN-g signaling pathway, is sucient for antigen presentation. . Following digestion of the PCR products (10 ml) by DdeI (Promega), the fragments were separated on a 10% polyacrylamide gel and detected by ethidium bromide staining. DdeI digestion of the 356 bp RT ± PCR products (lane 1) derived from all the pancreatic tumor lines except Hs766T generated two fragments (281 and 75 bp) (lanes 3 ± 12), representing the wild-type IRF-2 sequence. DdeI digestion of the RT ± PCR product from Hs766T cell produced three fragments (168, 113 and 75 bp) (lane 2), as the mutation at position 199 generates a novel DdeI site in the 281 bp fragment. (c) The mutant Hs766T IRF-2 has defective DNA binding activity. The expression vector for the mutant Hs766T IRF-2, Hs766T IRF-2/ pcDNA1, was constructed by substituting a wild-type cDNA fragment in IRF-2/pcDNA1 by the cDNA fragment derived from Hs766T which encompasses the mutated nucleotide at position 199 (see Materials and methods). IRF-2/pcDNA1 and Hs766T IRF-2/pcDNA1 were used as the templates to synthesize the wild-type IRF-2 (WT IRF-2) and the mutant IRF-2 (Hs766T IRF-2), respectively, by in vitro transcription and translation, as described in Materials and methods. Left panel: The in vitro translation eciency of the mutant IRF-2 was compared to that of the wild-type IRF-2 by quantifying the 35 S-methionine labeled in vitro translated proteins. The 35 S-methionine labeled in vitro translated proteins (2 ml) were analysed by SDS ± PAGE and autoradiography. The in vitro translation reaction without the RNA template (2 ml) served as negative control (neg ctrl). Right panel: The in vitro translated mutant Hs766T IRF-2 (1 ml, lane 1) and wild-type IRF-2 (1 ml, lane 2) were analysed by EMSA using the 785/+1 region of the CIITA type IV promoter as a probe. The rabbit reticulocyte lysate (1 ml) served as negative control (lane 3 We found that the CIITA noninducible pancreatic tumor cell line, Hs766T, has defective IRF-2 binding activity ( Figure 6 ). Sequence analysis of the IRF-2 from this cell line identi®ed a missense mutation in the DNA binding domain of IRF-2, which resulted in the substitution of the Phe by Ser at position 34. The position 34 Phe is present in all known IRF family members (Escalante et al., 1998) . This is the ®rst report of an IRF-2 mutation in a human tumor cell line. Functional analysis of the mutant IRF-2 showed that it does not have DNA binding or transactivating activity (Figure 7c and d) . Alteration of this residue might aect the protein folding and thus its contact with the DNA. It is also possible that the exchange of Phe to Ser may aect IRF-2 DNA binding by altering the phosphorylation status of IRF-2. A previous report demonstrated that IRF-2 is phosphorylated exclusively at Ser residues and can be phosphorylated by the serine/threonine protein kinases, PKA, PKC, and casein kinase II (CK2) (Birnbaum et al., 1997) .
Our results indicated that both IRF-1 and IRF-2 are essential for IFN-g induction of CIITA, which controls the expression of MHC class II proteins important for maintaining the immunogenicity of the tumor cells. Deletions and inactivating point mutations of IRF-1 have been found in human myelodysplasia/leukemia (Willman et al., 1993; Harada et al., 1994) and gastric tumors (Nazawa et al., 1998) . The inactivating mutation of IRF-2 in a pancreatic tumor cell line raises the question of whether IRF-2 mutations could have an impact on tumor immunogenicity. It will also be important to determine whether IRF-2 mutations are relevant to other tumor phenotypes not necessarily related to the anti-tumor immune response, such as lack of growth control or resistance to apoptosis.
Materials and methods
Cell cultures
The human pancreatic carcinoma cell lines were obtained from American Type Culture Collection (ATCC) and propagated according to ATCC instructions.
Preparation of reporter constructs
Construction of CIITA P4/785 and mutCIITA P4/ 785 The CIITA P4/785 construct was generated by annealing an oligonucleotide representing nucleotides 790 to 715 of the sense strand of the CIITA Type IV promoter (Muhlethaler-Mottet et al., 1997) with an oligonucleotide representing nucleotides 731 to +1 of the anti-sense strand and containing an XhoI site at the 5' end. The annealed oligonucleotides were then extended with Sequenase (United States Biochemical), digested with SacI and XhoI, and ligated into the SacI and XhoI sites of pGL3Basic (Promega). The mutCIITA P4/785 construct that has the mutant IRF-E was produced in the same way as the CIITA P4/785 construct except that two G residues at position 762 and 760 of the anti-sense oligonucleotide were substituted with two A residues. Both constructs were veri®ed by DNA sequencing.
Construction of CIITA P4/7309 A 347 bp DNA fragment encompassing the CIITA Type IV promoter from 7309 to +38 was generated by PCR from lymphoblastoid genomic DNA (RM, Research Genetics, Inc.). The product was cloned into the PCR2.1 vector (Invitrogen), excised with XhoI and HindIII, and inserted into HindIII and XhoI digested pGL2Basic (Promega). The ®nal construct was con®rmed by DNA sequencing.
GBP promoter reporter construct The human GBP promoter reporter construct, hGBP-Luc, which contains 7216 to +19 region of the human GBP promoter (Lew et al., 1991) upstream of a luciferase gene cloned into pGEM-1 vector (Promega), was kindly provided by Tetsuya Yamagata (University of Tokyo).
RNase protection assay (RPA) 32 P-labeled anti-sense CIITA probe, which protects a fragment corresponding to position 2913 to 3263 of the CIITA mRNA (Steimle et al., 1993) , was prepared by in vitro transcription of SalI digested CIITA cDNA plasmid, KS/ CIITA/HindIII 0.35a (a generous gift from Bernard Mach, University of Geneva) by T7 polymerase. The GBP RPA probe, which protects a 138 bp mRNA fragment, was prepared by in vitro transcription of HindIII digested GBP plasmid, pGT7 (a generous gift from Thomas Decker, Fraunhofer Institute of Toxicology) by T7 polymerase. The g-actin RPA probe was generated as previously described (Blanck et al., 1990; Lu et al., 1996) . RPA was performed using 10 mg of cytoplasmic RNA prepared from cells either untreated or treated with recombinant human IFN-g (Genzyme) at 400 U/ml for 48 h, as previously described (Blanck et al., 1990; Lu et al., 1996) . Preparation of nuclear extracts
The crude nuclear extracts were prepared according to the protocol described by Dignam et al. (1983) . Protein concentration was determined using the BCA protein assay reagent (Pierce Chemical).
Western blot analysis
Nuclear extracts (40 mg) were analysed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis on a 10% polyacrylamide gel. After electrophoresis, the proteins were transferred to a PolyScreen TM PVDF transfer membrane (NEN Research Products) in a buer containing 25 mM Tris, 192 mM glycine, and 20% methanol overnight at 48C. The membrane was blocked by incubation overnight at 48C in PBS containing 5% dried milk and 0.1% Tween 20 and then probed overnight at 48C with anti-IRF-2 antibody (Santa Cruz Biotechnology) diluted at 1 : 1000. The membrane was then rinsed wtih PBS containing 0.1% Tween 20 and incubated for 1 h with horseradish peroxidase-coupled goat anti-rabbit antibody at a dilution of 1 : 1000. The reaction was then detected by ECL reagents (Amersham) as recommended by the manufacturer.
In vitro transcription and translation
The IRF-1 and IRF-2 expression vectors, IRF-1/pcDNA1 (Cha and Deisseroth, 1994) and IRF-2/pcDNA1 (Cha and Deisseroth, 1994 ) (generous gifts of Ying Cha Henderson, MD Anderson Cancer Center), were used to generate in vitro translated IRF-1 and IRF-2, respectively. For full length IRF-1 and IRF-2, 200 ng IRF-1/pcDNA1 and IRF-2/ pcDNA1 plasmids, linearized by XhoI and XbaI, respectively, and transcribed in vitro by T7 RNA polymerase (Promega) as described (Reith et al., 1990) . For C-terminal truncated IRF-2, termed IRF-2/T, IRF-2/pcDNA1 was linearized by BglII, which generated a C-terminal truncated IRF-2 cDNA fragment encompassing the 5' untranslated region and the coding sequence from amino acids 1 ± 224. In vitro translation was performed using nuclease-treated rabbit reticulocyte lysate (Promega) according to the manufacturer's recommendations.
Electrophoretic mobility shift assay (EMSA)
The wild-type and mutant CIITA IRF-E containing fragments, which correspond to 785 to +1 of the CIITA Type IV promoter, were generated by SacI and XhoI double digestion of the CIITA P4/785 and mutCIITA P4/785 promoter luciferase plasmids, respectively (Figure 1) . The wild-type CIITA IRF-E fragment (200 ng) was labeled by a Klenow ®ll-in reaction (Sambrook et al., 1989) . For the hGBP IRF-E probe, two complementary oligonucleotides containing the IRF-E and its¯anking sequences (Lew et al., 1991) were synthesized (Integrated DNA Technologies) and mixed at an equal molar ratio in TE buer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The mixture was heated to 708C for 5 min followed by slow cooling. The annealed doublestranded oligonucleotide was labeled by the Klenow ®ll-in reaction. The sequences of the synthesized wild-type and mutant hGBP IRF-E oligonucleotides (7147 to 7102) are as follows: wild-type, 5 '-CAGTGATTTGAACGAAGT-ACTTTCAGTTTCATATT-ACTCTAAATCC-3' (sense strand), 5'-GGATTTAGAG-TA ATAT GAAACTGAAAG-ACT TCGT TCAAATCA -3' (anti-sense strand); mutant, 5'-C AGTGAT TTGA ACGAA-GTA CTcgagGTT TCAT AT-C-3' (sense strand), 5'-GGATTTAGAGTAATATGAAACctcgAGT ACTTCGTT CAAA-TCA-3' (anti-sense strand). The IRF-E is indicated by the underlined nucleotides. The changed nucleotides in the mutant hGBP-IRF-E are shown as lowercase type.
EMSAs were performed according to the method described by Yu et al. (1995) except as indicated in the Figure legends . EMSA experiments of CIITA IRF-E with nuclear extracts (Figures 4c and 6b and 6c) were performed as those with in vitro translated proteins described above, except that 80-fold molar excess unlabeled mutant CIITA IRF-E fragments were included in all the reactions with 10 mg of crude nuclear extract to eliminate the nonspeci®c binding.
Transfections and reporter gene assays
MIAPaCa-2 cells (2610 6 cells per 10-cm dish) were transfected by calcium phosphate precipitation (Kingston et al., 1997) . Each transfection was repeated ®ve times. Four hours after transfection, cells were washed twice with PBS and fed with 10 ml fresh medium. Cells were then incubated in the absence or presence of 400 U/ml IFN-g at 378C, 7.5% CO 2 for 24 h before harvesting. After pelleting, cell extracts were prepared for assay of luciferase activity according to manufacturer's instructions (Promega). Light emissions were quanti®ed by using a liquid scintillation counter (Beckman). Each sample was counted ten times consecutively, and the luciferase activity was measured by averaging the middle six counts. To ensure that luciferase activity was not aected by the time delay caused by assaying multiple samples, the ®rst sample was re-assayed at the end of a set of multiple samples.
Isolation and subcloning of the mutant Hs766T IRF-2
Reverse transcription was performed by the random priming method using 5 mg of cytoplasmic RNA from Hs766T cells and Superscript II RNases H(7) reverse transcriptase (GIBCO BRL) according to manufacturer's recommendation. The cDNA was subjected to PCR reaction with a pair of primers located at exon 1 (5'UTR) and exon 4, respectively, of IRF-2. The sequences of the PCR primers are as follows: IRF2BP18: 5'-CCGAAGCTTCCATTTCA-CACACCCTAGC, IRF2BP367: 5'-TCAGGCAAGGAATT-CATGGCG. A HindIII site was incorporated into the 5' end of IRF2BP18 whereas IRF2BP367 has an intrinsic EcoRI site. Forty cycles of PCR ampli®cation were performed by using the Taq polymerase (Fisher) under the following condition: 958C for 1 min, 558C for 1 min, and 728C for 1 min. The PCR product was digested with HindIII and EcoRI and gel puri®ed. The puri®ed fragment was then cloned into HindIII and EcoRI sites of PUC13 to generate Hs766T IRF2/PUC13 and sequenced by ABI Prism 377 DNA Sequencer. For construction of the mutant Hs766T IRF-2 expression vector, Hs766T IRF-2/pcDNA1, Hs766T IRF2/PUC13 was digested with HindIII and NsiI to generate the IRF-2 cDNA fragment encompassing the mutated nucleotide. The fragment was then subcloned in-frame into HindIII and NsiI digested IRF-2 expression vector, IRF-2/ pcDNA1, substituting for the wild-type IRF-2 cDNA fragment.
